Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
तुलना करने के लिए मीट्रिक्स | XERS | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधXERSपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −17.3x | −0.1x | −0.5x | |
PEG अनुपात | −0.49 | 0.06 | 0.00 | |
क़ीमत/बुक | −22.2x | 2.9x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 3.5x | 2.5x | 2.9x | |
अपसाइड (विश्लेषक लक्ष्य) | 38.7% | 102.8% | 49.4% | |
उचित मूल्य अपसाइड | अनलॉक करें | 14.8% | 8.2% | अनलॉक करें |